Delivery Order W91QEX19D0001-W91QEX20F00A9

The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded an Other Transaction Agreement to Emergent Biosolutions Canada Inc. valued at $34.6 million to support the development of human immune globulin (COVID-HIG) manufactured from human plasma with antibodies to SARS-CoV-2. The contract aims to prevent coronavirus disease (COVID-19) through October 2022. Performance will take place at Emergent Biosolutions Canada Inc.'s facility in Ottawa,...

The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded Astrazeneca Pharmaceuticals LP a $439.2 million Other Transaction Agreement to deliver a "COVID-19" monoclonal antibody therapeutic prototype. Performance will occur in Talleyville, Delaware through August 2022. As part of the larger Joint Project Manager for Medical Countermeasure Systems portfolio addressing chemical and biological threats, this appears to support the development...

The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded a $5.7 million other transaction agreement to 60 Degrees Pharmaceuticals, Inc., doing business as 60P, for the development of a "COVID-19" PROTOTYPE TEFONEQUINE. The prime contractor, 60P, will deliver prototype equine antibodies for the treatment and prevention of COVID-19 under the contract. The funding agency is pursuing medical countermeasures to combat the ongoing pandemic...

The Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response awarded a $29.9 million delivery order to Protein Sciences Corporation under the Pandemic Influenza Preparedness and Response 2016-2021 master IDIQ contract. The delivery order is for non-clinical and Phase I clinical studies of a stabilized pre-fusion trimer of the spike protein COVID-19 vaccine candidate reconstituted with two adjuvants, AS03 and AF03, to be performed in Meriden,...

The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded a $16.5 million Other Transaction Agreement to Rigel Pharmaceuticals Inc. to support the development of a therapeutic to treat COVID-19. The prototype effort will take place in South San Francisco, California through May 2023. No set-aside designation was applied to this award made under the "COVID-19" PROTOTYPE DEVELOPMENT OF A THEREAPUTIC TO TREAT COVID-19 solicitation. As the...

The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded a $12 million firm fixed price delivery order to Cepheid, a subsidiary of Danaher Corporation, to support its XPCOV2/FLU/RSV-10 program. The contract calls for Cepheid to provide products and services for the detection of COVID-19, influenza, and respiratory syncytial virus from a single patient sample at its place of performance in Aberdeen, Maryland. The period of performance is from...

This definitive contract from the Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense (JPEO-CBRND) awards Microbiologics, Inc. $13.6 million to deliver technology transfer of reporter VN assay in support of advanced SARS-CoV-2 medical countermeasure therapeutics. The solicitation sought proposals to manufacture and fill-finish a minimum of 100,000 treatment courses by March 2021 to treat the indicated U.S. population, with candidate therapeutics...

The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded a $100.3 million other transaction agreement to Clinical Enterprise, Inc. to support the expansion of U.S. testing using coordination hubs 3 and 4. The prime contractor, Clinical Enterprise, Inc., will deliver coordination hub services for COVID-19 testing in Framingham, Massachusetts under the contract, which runs from May 2021 through December 2022. No set aside designation or subcontractors...

This federal contract award, valued at $7,521,000.00, was issued by the Centers for Disease Control and Prevention (CDC) to Protein Sciences Corp, a for-profit manufacturer, to conduct research, development, manufacturing, and testing of vaccine candidates, antigens, proteins, seed lots, and assays to support medical countermeasure preparedness against influenza strains and COVID-19. The award is part of the Department of Health and Human Services' (HHS) Office of the Assistant Secretary for...

This purchase order, valued at $6.96 million, was awarded by the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response to Monogram Biosciences, Inc. to establish high-throughput SARS-CoV-2 neutralizing antibody immunoassay capability and test human serum samples. As a subsidiary of Laboratory Corporation of America Holdings, Monogram will perform this work establishing a testing capability and analyzing samples at its facility in South San...